{"id":"W4387811984","doi":"10.1016/j.annonc.2023.09.1543","title":"41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Genentech; Servier; European Society for Medical Oncology; CRIS Cancer Foundation; Astellas Pharma; Sierra Oncology; Incyte; Regeneron Pharmaceuticals; Eli Lilly and Company; AstraZeneca; American Society of Clinical Oncology; Eisai; Sociedad Española de Oncología Médica; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; PharmaMar; Celgene","keywords":"Enzalutamide; Medicine; Prostate cancer; Pharmacology; Drug; Cancer; Internal medicine","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003552743,0.0004443778,0.000311141,0.0002915623,0.0002641391,0.0003309431,0.0003235725,0.0007066803,0.003304986],"category_scores_gemma":[0.0002065981,0.0002014866,0.000378021,0.0002316957,0.0002763615,0.0002959469,0.0001690429,0.0007805504,0.0007274633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005175965,"about_ca_system_score_gemma":0.000745088,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002748984,"about_ca_topic_score_gemma":0.002464268,"domain_scores_codex":[0.9997848,0.00005364798,0.000007883738,0.0000375414,0.00006647043,0.00004963766],"domain_scores_gemma":[0.9999099,0.00001355258,0.00001412971,0.000008335072,0.00002532129,0.00002881245],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001568404,0.0008221219,0.0002976835,0.000169884,0.00004888107,0.0002230912,0.0000729715,0.002103972,0.9746098,0.0004847689,0.001378882,0.01821947],"study_design_scores_gemma":[0.0002670038,0.01238725,0.0018945,0.0000151831,0.00007041536,0.000426637,0.00004191486,0.003044019,0.9707809,0.00009518996,0.0109545,0.00002248907],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9791505,0.002474306,0.005767085,0.0004629044,0.0001732927,0.0004673985,0.001623292,0.0002957844,0.009585362],"genre_scores_gemma":[0.9728016,0.002663431,0.005849028,0.0002194076,0.00002273098,0.0001973095,0.002068884,0.00009098673,0.01608668],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003304986,"threshold_uncertainty_score":0.0110563,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.392455333242991,"score_gpt":0.526931954523353,"score_spread":0.1344766212803619,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}